

RESILIENCE

DIGITAL ONCOLOGY

Resilience accelerates clinical research on remote patient monitoring in oncology with the RC-102 Study

Press release - Paris, Thursday September 12th, 2024

Resilience, the remote patient care solution in oncology, announces the launch of the Resilience Care - 102 study (RC-102). This large scale randomized controlled clinical trial, which will be carried out on 1458 patients in 45 different healthcare facilities, highlights Resilience's position as a major player in clinical research in the field of medical remote monitoring and in remote patient care.

Make RC-102 the new benchmark clinical study in oncology remote monitoring

Resilience Care - 102 (RC-102) is a multicentric, randomized controlled trial that compares remote monitoring (RPM) by Resilience PRO to care as usual (routine care, conventional monitoring) in patients diagnosed with cancer receiving systemic treatments. RC-102 will launch in the first quarter of 2025 and will include 1458 patients from 45 healthcare facilities. The primary endpoint will assess the improvement in quality of life, while secondary objectives will evaluate the benefits in terms of morbidity and medico-economic value. The study population is large, and mirrors real life conditions: patients with localized, locally advanced or metastatic disease; receiving any type of systemic therapy, including the most recent ones - chemotherapy, hormonal therapy, immunotherapy, targeted therapies, antibody drug conjugates, etc.) will be enrolled.

In recent years, several randomized, prospective trials have demonstrated the clinical and organizational benefits of RPM in oncology. Better management of patients' symptoms through RPM leads to a reduction in severe toxicities (morbidity), which, in turn, decreases emergency room visits and hospitalizations, shortens the length of hospital stays, and extends the duration of anticancer treatments. These benefits collectively enhance patients' quality of life and overall survival. These large studies were carried out mainly on patients with locally advanced or metastatic cancer, and whose tumor types were solid tumors. The RC-102 study will provide an additional level of evidence for all types of cancer patients, including those with localized tumor stages, hematologic malignancies, and whose treatments administered are the most novel.

For **Professor Florian Scotté**, Head of Département Interdisciplinaire d'Organisation des Parcours Patients (DIOPP) at Gustave Roussy, Associate Professor at the University of Paris Saclay and RC-102's Principal Investigator and Coordinator: « **The RC-102 study, conducted among a large cohort of cancer patients, representative of the real life population, will contribute to the development of remote medical monitoring in oncology and will allow related authorities globally to accelerate reimbursement of digital medical devices for better patient care.** »

Contribute to research to define new ways of treating patients

In October of 2023, following a positive opinion from the Haute Autorité de Santé (HAS), Resilience PRO became the first medical device in oncology to receive a full approval in France (i.e. registered as a brand name on the List of Medical Remote Monitoring Activities (LATM), thus allowing its reimbursement by the French National Insurance system (Assurance Maladie). Obtaining reimbursement has been a major turning point for Resilience, which pursues its strong ambition to define a new approach to patient care and personalize the care pathway. The launch of RC-102 represents a new paramount step for the company.

« RC-102, with its rigorous design, will generate robust evidence to further enhance the clinical and organizational benefits of our approach. The launch of this ambitious study in turn allows Resilience to position itself as a major player in clinical research in oncology, in the field of remote monitoring and remote patient care », emphasizes **Dr. Charles Ferté**, Chief Medical & Patient Experience Officer at Resilience.

In addition, Resilience is participating in more than 19 multicentric clinical studies carried out by or in collaboration with cooperative groups, partnered academic centers or industrial companies. These phase I to III studies cover solid tumors, hematology, and surgery in adult patients or children with cancer. Furthermore, the company is advancing the scientific valorization of data generated in remote monitoring with publications and presentations found in leading peer reviewed journals and international conferences. At ESMO 2024, Resilience will highlight five posters related to the impact of remote monitoring in thoracic cancers, gastrointestinal cancers, and elderly patients: the factors affecting complexity of care and the influence of patient health related behaviors on clinical outcomes. The results of these different studies are based on data from thousands of patients monitored in routine care.

About Resilience

Resilience offers a comprehensive Remote Patient Care solution dedicated to cancer patients and healthcare professionals. Combining a mobile application with Remote Patient Monitoring platform, Resilience ensures better care by personalizing, humanizing, and improving the care pathway. The mobile application supports individuals affected by cancer in managing treatment-related side effects and fostering self-care. Meanwhile, the Remote Patient Monitoring platform, a Class IIa medical device, enables healthcare professionals to better understand and improve patient care. Founded in February 2021 by Céline Lazorthes and Jonathan Benhamou, Resilience was co-founded with Gustave Roussy, the leading cancer center in Europe. The company partners with more than 100 centers and supports over 10,000 patients. www.resilience.care

Press contact: Sibylle PICHOT - Head of Communication & Brand – sibylle.pichot@resilience.care